|
Digested pellet deposits (microclots) from acute COVID-19 samples vs digested plasma from Control samples
|
|---|
|
These proteins are present in both sample types; and a fold change value more than 1 = the protein that more prevalent inside the digested pellet deposits from COVID-19 samples. These proteins were concentrated inside the digested pellet deposits
|
|
Protein name
|
Fold change
|
p-value
|
|---|
|
von Willebrand Factor
|
4.5
|
0.02
|
|
Complement component C4b
|
4.2
|
0.05
|
|
C-reactive protein
|
18.7
|
0.003
|
|
Digested pellet deposits from Long COVID/PASC microclots samples vs digested plasma from Control samples
|
|---|
|
These proteins are present in both sample types; and a fold change value more than 1 = the protein that more prevalent inside the digested pellet deposits from Long COVID/PASC samples. These proteins were concentrated inside the digested pellet deposits
|
|
Coagulation factor XIII A chain
|
6.9
|
0.001
|
|
Plasminogen
|
3
|
0.001
|
|
Fibrinogen alpha chain
|
4.1
|
0.0001
|
|
α2 antiplasmin (α2AP)
|
7.98
|
0.0002
|
|
von Willebrand Factor
|
10.2
|
0.001
|
|
C-reactive protein
|
11.2
|
0.007
|
|
Serum Amyloid A (SAA4)
|
17.5
|
0.01
|
|
Complement component C7
|
20
|
0.0002
|
|
Digested pellet deposits from Long COVID/PASC microclots samples vs digested pellet deposits (microclots) from acute COVID-19 samples
|
|---|
|
These proteins are present in both sample types; and a fold change value more than 1 = the protein that more prevalent inside the digested pellet deposits from Long COVID/PASC samples. These proteins were concentrated inside the digested pellet deposits
|
|
Plasminogen
|
2.3
|
0.0007
|
|
Fibrinogen β chain
|
2.8
|
0.0007
|
|
Coagulation factor XIII B
|
2.7
|
0.01
|
|
Fibrinogen α chain
|
3.1
|
0.0002-
|
|
Complement component C6
|
7.5
|
0.01
|
|
α2 antiplasmin (α2AP)
|
9.2
|
0.0003
|
|
Complement factor 1
|
25
|
0.0009
|
|
Digested plasma from T2DM samples (after 1st trypsinization step) vs Long COVID/PASC digested pellet deposits (microclots) (after 2nd trypsinization step)
|
|---|
|
These proteins are present in both sample types; and a fold change value more than 1 = the protein that more prevalent inside the digested plasma from the Long COVID samples
|
|
CytoskeletalKeratin, type I
|
24.7
|
0.01
|
|
Cytoskeletal Keratin, type II
|
14
|
0.02
|
|
C1q subcomponent subunit B
|
1
|
0.03
|
|
Digested plasma from control plasma samples vs digested plasma samples from T2DM samples (both plasma sample analysed after 1st trypsinization step)
|
|---|
|
These proteins are present in both sample types; and a fold change value more than 1 = the protein that more prevalent inside the digested plasma from the diabetes samples
|
|
Complement C1r subcomponent-like protein
|
1.5
|
0.04
|
|
SAA1
|
2.5
|
0.03
|
- All sample types underwent a two-step trypsinization process. Controls vs acute COVID-19; Controls vs Long COVID/PASC; acute COVID-19 vs Long COVID/PASC. The proteins showed here are in both sample types; and value more than 1 = the protein more prevalent in a specific digested pellet deposit. We also compared fold changes between digested plasma (after 1st trypsinisation step) of samples from controls and Type 2 Diabetes Mellitus (T2DM) and between samples from T2DM and Long COVID/PASC (supernatant after 1st trypsinization step only)
